Medline PE Backers Finalize $2.68 Billion Upsized Stock Sale
MDLN is trading near its 52-week low of $35.44 (3.8% above the low) on elevated volume (2.0× avg).
Summary
Medline's major private equity shareholders, including Blackstone and Hellman & Friedman, have closed their upsized secondary offering, selling 72.55 million shares at $37.00 each, totaling $2.68 billion. This follows a series of SEC filings over the past week detailing the registration, upsizing, and pricing of this significant stock sale. The company did not receive any proceeds from the offering. This continued divestment by large institutional holders, especially with the stock trading near its 52-week low, increases the share float and can exert downward pressure on the stock price.
At the time of this announcement, MDLN was trading at $36.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $48.3B. The 52-week trading range was $35.44 to $50.88. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.